In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli. / Kromann, Sofie; Hvidtfeldt, Anna; Boye, Mette; Sørensen, Dorte Bratbo; Jørgensen, Steffen; Nielsen, Jens Peter; Olsen, Rikke Heidemann.

In: BMC Microbiology, Vol. 19, No. 1, 12, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kromann, S, Hvidtfeldt, A, Boye, M, Sørensen, DB, Jørgensen, S, Nielsen, JP & Olsen, RH 2019, 'In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli', BMC Microbiology, vol. 19, no. 1, 12. https://doi.org/10.1186/s12866-018-1383-5

APA

Kromann, S., Hvidtfeldt, A., Boye, M., Sørensen, D. B., Jørgensen, S., Nielsen, J. P., & Olsen, R. H. (2019). In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli. BMC Microbiology, 19(1), [12]. https://doi.org/10.1186/s12866-018-1383-5

Vancouver

Kromann S, Hvidtfeldt A, Boye M, Sørensen DB, Jørgensen S, Nielsen JP et al. In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli. BMC Microbiology. 2019;19(1). 12. https://doi.org/10.1186/s12866-018-1383-5

Author

Kromann, Sofie ; Hvidtfeldt, Anna ; Boye, Mette ; Sørensen, Dorte Bratbo ; Jørgensen, Steffen ; Nielsen, Jens Peter ; Olsen, Rikke Heidemann. / In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli. In: BMC Microbiology. 2019 ; Vol. 19, No. 1.

Bibtex

@article{3b61ef7d2aef4acf9c2e9d91b69626c1,
title = "In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli",
abstract = "Background: Antimicrobial helper-compounds may reverse antimicrobial resistance. Sertraline, a antidepressant drug, has been suggested as a tetracycline helper-compound. Tetracycline is the preferred antimicrobial for treatment of enteric diseases in pigs. This study is the first to evaluate the potency of sertraline as a tetracycline adjuvant in pigs. Methods: Forty-eight nursery pigs were divided into four treatment groups: Tetracycline, sertraline, tetracycline/sertraline or un-medicated control. Fecal and ileal samples were obtained before treatment, 48 h and nine days after five days of treatment, respectively. Colony forming units (CFU) of tetracycline resistant coliforms in each sample (ileal or fecal) and CFU of an orally inoculated tetracycline-resistant strain of Escherichia coli were determined at each sampling point. The microbiome of fecal and ileal and samples was analyzed by sequencing of the 16S V3-V4 region. Results: The results did not provide evidence that sertraline in combination with tetracycline has any impact on tetracycline resistant bacteria in either fecal or ileum samples, while in the tetracycline treated group of pigs, an increase in the prevalence of a tetracycline resistant indicator strain of Escherichia coli shortly after ended five-day treatment was observed. The ileal samples obtained shortly after ended treatment showed treatment-associated changes in the composition of the microbiota in the groups of pigs treated with tetracycline (+/-) sertraline. While tetracycline treatment increased the abundance in the reads of E. coli, sertraline/tetracycline treatment led to increased abundances of Streptococcus spp. and decreased abundances of Lactobacillus spp. However, all observed differences (on CFU counts and microbiota composition) between groups shortly after treatment had diminished in less than two weeks after last treatment day. Conclusions: Sertraline (+/-) tetracycline treatment did not reduce the long-term level of tetracycline-resistant bacteria in the feces or small intestine contents of piglets compared to the un-medicated control group of pigs. The result of this study reflects the importance of in vivo studies for confirmation of the antimicrobial helper-compound potential of an in vitro active compound.",
keywords = "Antimicrobial resistance, E. coli, Pigs, Sertraline, Synergy, Tetracycline",
author = "Sofie Kromann and Anna Hvidtfeldt and Mette Boye and S{\o}rensen, {Dorte Bratbo} and Steffen J{\o}rgensen and Nielsen, {Jens Peter} and Olsen, {Rikke Heidemann}",
year = "2019",
doi = "10.1186/s12866-018-1383-5",
language = "English",
volume = "19",
journal = "B M C Microbiology",
issn = "1471-2180",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - In vitro synergy of sertraline and tetracycline cannot be reproduced in pigs orally challenged with a tetracycline resistant Escherichia coli

AU - Kromann, Sofie

AU - Hvidtfeldt, Anna

AU - Boye, Mette

AU - Sørensen, Dorte Bratbo

AU - Jørgensen, Steffen

AU - Nielsen, Jens Peter

AU - Olsen, Rikke Heidemann

PY - 2019

Y1 - 2019

N2 - Background: Antimicrobial helper-compounds may reverse antimicrobial resistance. Sertraline, a antidepressant drug, has been suggested as a tetracycline helper-compound. Tetracycline is the preferred antimicrobial for treatment of enteric diseases in pigs. This study is the first to evaluate the potency of sertraline as a tetracycline adjuvant in pigs. Methods: Forty-eight nursery pigs were divided into four treatment groups: Tetracycline, sertraline, tetracycline/sertraline or un-medicated control. Fecal and ileal samples were obtained before treatment, 48 h and nine days after five days of treatment, respectively. Colony forming units (CFU) of tetracycline resistant coliforms in each sample (ileal or fecal) and CFU of an orally inoculated tetracycline-resistant strain of Escherichia coli were determined at each sampling point. The microbiome of fecal and ileal and samples was analyzed by sequencing of the 16S V3-V4 region. Results: The results did not provide evidence that sertraline in combination with tetracycline has any impact on tetracycline resistant bacteria in either fecal or ileum samples, while in the tetracycline treated group of pigs, an increase in the prevalence of a tetracycline resistant indicator strain of Escherichia coli shortly after ended five-day treatment was observed. The ileal samples obtained shortly after ended treatment showed treatment-associated changes in the composition of the microbiota in the groups of pigs treated with tetracycline (+/-) sertraline. While tetracycline treatment increased the abundance in the reads of E. coli, sertraline/tetracycline treatment led to increased abundances of Streptococcus spp. and decreased abundances of Lactobacillus spp. However, all observed differences (on CFU counts and microbiota composition) between groups shortly after treatment had diminished in less than two weeks after last treatment day. Conclusions: Sertraline (+/-) tetracycline treatment did not reduce the long-term level of tetracycline-resistant bacteria in the feces or small intestine contents of piglets compared to the un-medicated control group of pigs. The result of this study reflects the importance of in vivo studies for confirmation of the antimicrobial helper-compound potential of an in vitro active compound.

AB - Background: Antimicrobial helper-compounds may reverse antimicrobial resistance. Sertraline, a antidepressant drug, has been suggested as a tetracycline helper-compound. Tetracycline is the preferred antimicrobial for treatment of enteric diseases in pigs. This study is the first to evaluate the potency of sertraline as a tetracycline adjuvant in pigs. Methods: Forty-eight nursery pigs were divided into four treatment groups: Tetracycline, sertraline, tetracycline/sertraline or un-medicated control. Fecal and ileal samples were obtained before treatment, 48 h and nine days after five days of treatment, respectively. Colony forming units (CFU) of tetracycline resistant coliforms in each sample (ileal or fecal) and CFU of an orally inoculated tetracycline-resistant strain of Escherichia coli were determined at each sampling point. The microbiome of fecal and ileal and samples was analyzed by sequencing of the 16S V3-V4 region. Results: The results did not provide evidence that sertraline in combination with tetracycline has any impact on tetracycline resistant bacteria in either fecal or ileum samples, while in the tetracycline treated group of pigs, an increase in the prevalence of a tetracycline resistant indicator strain of Escherichia coli shortly after ended five-day treatment was observed. The ileal samples obtained shortly after ended treatment showed treatment-associated changes in the composition of the microbiota in the groups of pigs treated with tetracycline (+/-) sertraline. While tetracycline treatment increased the abundance in the reads of E. coli, sertraline/tetracycline treatment led to increased abundances of Streptococcus spp. and decreased abundances of Lactobacillus spp. However, all observed differences (on CFU counts and microbiota composition) between groups shortly after treatment had diminished in less than two weeks after last treatment day. Conclusions: Sertraline (+/-) tetracycline treatment did not reduce the long-term level of tetracycline-resistant bacteria in the feces or small intestine contents of piglets compared to the un-medicated control group of pigs. The result of this study reflects the importance of in vivo studies for confirmation of the antimicrobial helper-compound potential of an in vitro active compound.

KW - Antimicrobial resistance

KW - E. coli

KW - Pigs

KW - Sertraline

KW - Synergy

KW - Tetracycline

U2 - 10.1186/s12866-018-1383-5

DO - 10.1186/s12866-018-1383-5

M3 - Journal article

VL - 19

JO - B M C Microbiology

JF - B M C Microbiology

SN - 1471-2180

IS - 1

M1 - 12

ER -

ID: 217109869